A01N37/12

Volatile organic compound formulations having antimicrobial activity

The present subject matter includes novel chemical formulations having antimicrobial, antifungal, antiseptic, and related effect in a wide range of applications for treating or preventing infections as well as treating various surfaces that may become tainted with infectants. In some embodiments, the formulation includes isoamyl hexanoates and at least one of propanoic and/or isobutyric acid.

Volatile organic compound formulations having antimicrobial activity

The present subject matter includes novel chemical formulations having antimicrobial, antifungal, antiseptic, and related effect in a wide range of applications for treating or preventing infections as well as treating various surfaces that may become tainted with infectants. In some embodiments, the formulation includes isoamyl hexanoates and at least one of propanoic and/or isobutyric acid.

METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS
20220079150 · 2022-03-17 ·

The disclosure relates to methods and compositions for altering the production of one or more secondary plant metabolites comprising applying an effective amount of at least one elicitor, wherein the elicitor is a jasmonate or a salicylate, and combinations thereof. The disclosure further teaches compositions comprising effective amounts of the elicitors disclosed here. The disclosure further relates to methods and compositions for controlling plant pathogens, such as fungal pathogens.

METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS
20220079150 · 2022-03-17 ·

The disclosure relates to methods and compositions for altering the production of one or more secondary plant metabolites comprising applying an effective amount of at least one elicitor, wherein the elicitor is a jasmonate or a salicylate, and combinations thereof. The disclosure further teaches compositions comprising effective amounts of the elicitors disclosed here. The disclosure further relates to methods and compositions for controlling plant pathogens, such as fungal pathogens.

Topical compositions and methods for treating inflammatory skin diseases

Compositions and methods for treating skin conditions, ailments or diseases, such as autoinflammatory skin diseases such as psoriasis, dermatitis, pyoderma gangrenosum, palmoplantar pustulosis, prurigo nodularis and/or hidradenitis suppurativa, are described. The compositions comprise an agent that modulates the aryl hydrocarbon receptor, in particular an agent that agonizes the receptor. In one embodiment, the agent is indigo or a derivative of indigo, such as indirubin.

LOW-FOAM ADJUVANT COMBINATION FOR FORMULATIONS FOR CROP PROTECTION
20210315204 · 2021-10-14 ·

The invention relates to the technical field of adjuvant combinations with antifoam properties (antifoam adjuvant combinations) for crop protection formulations, in particular herbicidal formulations, and formulations containing said adjuvant combinations, as well as methods for producing said formulations.

In a preferred embodiment, the instant invention relates to aqueous formulations of water-soluble active crop protectant ingredients, in particular aqueous formulations of saltlike active crop protectant ingredients, and especially to formulations containing

LOW-FOAM ADJUVANT COMBINATION FOR FORMULATIONS FOR CROP PROTECTION
20210315204 · 2021-10-14 ·

The invention relates to the technical field of adjuvant combinations with antifoam properties (antifoam adjuvant combinations) for crop protection formulations, in particular herbicidal formulations, and formulations containing said adjuvant combinations, as well as methods for producing said formulations.

In a preferred embodiment, the instant invention relates to aqueous formulations of water-soluble active crop protectant ingredients, in particular aqueous formulations of saltlike active crop protectant ingredients, and especially to formulations containing

METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS HAVING RESISTANCE AGAINST Qo SITE INHIBITOR

The present invention provides a method for controlling a soybean rust fungus having an amino acid substitution of F129L on mitochondrial cytochrome b protein, by applying a compound represented by formula (I) [wherein Q represents a group represented by the following Q1, Q2, Q3, Q4 or Q5 (in the formulae, .circle-solid. represents a binding site to benzene ring); X represents an oxygen atom or NH; L represents CH.sub.2, an oxygen atom or NCH.sub.3; E represents a C6-C10 aryl group, etc.; R.sup.1 represents a C1-C3 chain hydrocarbon group or a cyclopropyl group, etc.; R.sup.2 represents a C1-C3 chain hydrocarbon group or a cyclopropyl group, etc.; R.sup.3 represents a C1-C3 alkoxy group or a C1-C3 chain hydrocarbon group, etc.; and n is 0, 1, 2, or 3] or its N oxide or an agriculturally acceptable salt thereof.

##STR00001##

METHOD FOR CONTROLLING SOYBEAN RUST FUNGUS HAVING RESISTANCE AGAINST Qo SITE INHIBITOR

The present invention provides a method for controlling a soybean rust fungus having an amino acid substitution of F129L on mitochondrial cytochrome b protein, by applying a compound represented by formula (I) [wherein Q represents a group represented by the following Q1, Q2, Q3, Q4 or Q5 (in the formulae, .circle-solid. represents a binding site to benzene ring); X represents an oxygen atom or NH; L represents CH.sub.2, an oxygen atom or NCH.sub.3; E represents a C6-C10 aryl group, etc.; R.sup.1 represents a C1-C3 chain hydrocarbon group or a cyclopropyl group, etc.; R.sup.2 represents a C1-C3 chain hydrocarbon group or a cyclopropyl group, etc.; R.sup.3 represents a C1-C3 alkoxy group or a C1-C3 chain hydrocarbon group, etc.; and n is 0, 1, 2, or 3] or its N oxide or an agriculturally acceptable salt thereof.

##STR00001##

Methods for enhancing the bio availability and exposure of a voltage-gated potassium channel opener
11135214 · 2021-10-05 · ·

In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.